Avitar's Oral Testing Technology a Hit in Construction Industry

  
    
  
  
    
      Avitar Inc. (“AVTI”) 
      (OTCBB:AVTI), manufacturers of nationally branded oral fluid testing 
      diagnostic devices and customized polyurethane applications used in 
      wound dressings, announced today that the Company’s 
      ORALscreen rapid test for drugs-of-abuse are being piloted and moving 
      towards nationwide deployment at two of the largest construction firms 
      in the United States.
    
    
      Peter Phildius, Avitar’s Chairman and CEO 
      said, “The construction industry represents a 
      significant business opportunity for Avitar, a revenue potential of $1M 
      over the next year. Industry leaders are now moving to incorporate Avitar’s 
      on-site oral fluid technology for random drug testing, as well as 
      pre-employment, post-accident, and reasonable suspicion applications, 
      previously done with traditional urine testing. We have also expanded 
      our client list of small to medium-sized contractors and continue to 
      develop a solid understanding of the needs of the construction sector, 
      where we believe our integrated drug-free workplace solutions offer true 
      value.”
    
    
      Avitar has been focusing on meeting construction safety requirements for 
      the past two years, and also continues to make progress educating and 
      gaining approvals from multiple union locals, including Carpenters, 
      Ironworkers, Steelworkers, IBEW, as well as the Longshoremen's Union 
      where Avitar products are being used at several seaports. Additionally, 
      State Governments are recognizing the value of oral fluid to the 
      construction sector. For example, the States of Hawaii and Georgia 
      recently passed legislation providing Worker's Compensation premium 
      discounts for the use of on-site oral fluid devices. In Hawaii, the 
      Carpenters Union spearheaded the change.
    
    
      About Avitar, Inc.
    
    
      Avitar Inc. develops, manufactures and markets innovative proprietary 
      products. Markets include fluid diagnostics, disease and clinical 
      testing, and customized applications for wound dressings. Principal 
      products include ORALscreen®, (the first 
      non-invasive, rapid, onsite oral fluid test for drugs-of-abuse), and 
      Hydrasorb®, (an absorbent topical dressing 
      for moderate to heavy exudating wounds). Avitar is also developing 
      diagnostic strategies for disease and clinical testing in the estimated 
      $25 billion in-vitro diagnostics market. Conditions targeted include 
      influenza, diabetes, and pregnancy. For more information, see Avitar's 
      website at http://www.avitarinc.com.
    
    
      Avitar Inc. is a fully reporting company whose stock trades on the OTCBB 
      under the symbol “AVTI.OB”.
    
    
      Forward-Looking Statements
    
    
      This release contains forward-looking statements that are subject to 
      risks and uncertainties including the development and marketing of new 
      applications and other risks that are detailed from time to time in the 
      Company’s filings with the Securities and 
      Exchange Commission. In view of such risks and uncertainties, the Company’s 
      actual results could differ materially from those anticipated in such 
      forward-looking statements.